Virpax Pharmaceuticals (VRPX) Financials

$0.00

$-0.22 (-99.95%)

As on 15-Sep-2026 16:00EDT

Market cap

$0 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	12.08	15.19	21.85	12.03	4.20	3.18
Operating Profit (EBIT)	-12.08	-12.94	-21.85	-12.03	-4.20	-3.18
Other Income	--	--	--	--	--	--
Profit before Tax	-12.07	-15.19	-21.65	-12.06	-4.34	-3.31
Provision for Tax	--	-0.01	-0.19	0.09	0.15	0.12
Profit after Tax (Net Income)	-12.07	-15.19	-21.46	-12.15	-4.49	-3.43
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-12.06	-4.34	-3.31

Liabilities ($ Mln)	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	-0.91	1.93	16.58	37.48	-4.22	-2.73
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	0.00	--	1.02	1.26
Current Liabilities	2.47	7.69	3.09	2.09	3.66	2.78
Total Liabilities	1.56	9.63	19.67	39.57	0.47	0.05

Assets ($ Mln)	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	--	--	--	--	0.39	--
Current Assets	1.56	9.63	19.67	39.57	0.07	0.05
Total Assets	1.56	9.63	19.67	39.57	0.47	0.05
Total Debt*	--	--	--	--	1.57	1.26
Net Current Assets	-0.91	1.93	16.58	37.48	-3.59	-2.73

Cashflow ($ Mln)	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	-16,712.90	-9.85	-17.85	-14.54	-1.38	-1.13
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	9,084.45	--	0.05	51.33	1.40	1.13
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	-2.84	-12.97	-18.32	-1.82	-1.00	-0.69
Cash EPS ($)	-2.84	-12.97	-18.32	-1.82	-1.00	-0.69
Adjusted Book Value ($)	--	1.65	14.15	5.61	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	-3,928.38	-8.41	-15.24	-2.18	-0.31	-0.23
Free Cash Flow per Share ($)	-3,928.38	-8.41	-15.24	-2.18	-0.31	-0.23

Profitability Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	-2,364.82	-164.09	-79.37	-69.75	217.94	317.63
ROE (%)	-2,364.82	-164.09	-79.37	-73.04	129.17	174.84
ROA (%)	-215.80	-103.68	-72.43	-60.69	-1,752.54	-6,341.13
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	0.00	62.02	-66.73	-472.29	-31.74	-21.17
Net Profit Growth (%)	20.56	29.21	-76.61	-170.72	-30.79	-29.92
EPS Growth (%)	0.78	0.29	-9.07	-0.83	-0.43	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	-0.13	-0.02	-0.03	-1.89	--	--
Price / Book Value	-1.77	0.19	0.04	0.61	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	126.34	3.90	0.84	1.17	--	--
Close Price ($)	9.50	80.00	155.58	857.50	--	--
High Price ($)	137.00	300.00	917.50	9,000.00	--	--
Low Price ($)	7.15	60.05	152.50	777.50	--	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	--	--	--	-0.37	-0.46
Short term debt to equity ratio	--	--	--	--	-0.13	-0.46
Current Ratio	0.63	1.25	6.36	18.96	0.02	0.02
Quick Ratio	--	--	--	--	--	0.02
Interest Coverage	-146.40	--	-205.73	-258.44	-28.34	-25.53

Operating Efficiency Ratios	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--